Review of dermatomyositis: Establishing the diagnosis and treatment algorithm

Journal of Dermatological Treatment

Volumn 24, Issue 6, 2013, Pages 418-421

  Strowd, Lindsay C ^a   Jorizzo, Joseph L ^a  

^a WAKE FOREST BAPTIST HEALTH   (United States)

Author keywords

Autoimmune; Inflammatory myopathy; Systemic immunosuppressants

Indexed keywords

AZATHIOPRINE; CALCIUM; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETANERCEPT; FLUDARABINE; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; RITUXIMAB; TACROLIMUS; VITAMIN D;

ALGORITHM; CLINICAL FEATURE; DERMATOMYOSITIS; DISEASE CONTROL; DRUG DOSE REDUCTION; ELECTROMYOGRAPHY; EVIDENCE BASED PRACTICE; HUMAN; HYPERPIGMENTATION; HYPOPIGMENTATION; LUPUS ERYTHEMATOSUS; NONHUMAN; OSTEOPOROSIS; PHOTOSENSITIVITY; POIKILODERMA; PRIORITY JOURNAL; PROGNOSIS; PRURITUS; REVIEW; SKIN ATROPHY; TELANGIECTASIA; UNSPECIFIED SIDE EFFECT;

ALGORITHMS; DERMATOMYOSITIS; HUMANS; IMMUNOSUPPRESSION; MUSCLE STRENGTH; PROGNOSIS;

EID: 84887929696     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.3109/09546634.2012.697540     Document Type: Review

References (48)

1. Bendewald MJ, Wetter DA, Li X, Davis MD. Incidence of dermatomyositis and clinically amyopathic dermatomyositis. Arch Dermatol. 2010;146:26-30
2. Jorizzo JL, Vleugels RA. n.d. DM. In: Bolognia J, Jorizzo JL, Schaffer JV, et al. (eds), Dermatology. 3rd ed. London, England: Mosby Elsivier; 2012
3. Ramanan AV, Feldman BM. Clinical outcomes in juvenile dermatomyositis. Curr Opin Rheumatol. 2002;14:658-662
4. Braverman IM. Skin signs of Systemic Disease. Philadelphia: WB Saunders Company, 1998
5. James WD, Berger TG, Elston DM. editors. Andrews' Disease of the Skin Clinical Dermatology. 10th ed. Canada: Saunders Elsivier, 2006
6. Seidman RJ. Skeletal muscle pathology. In Medscape Reference. Available from http://emedicine.medscape.com/article/1869808.accessed 8 June 2011
7. Pappu R, Seetharaman M. Polymoysitis. In Medscape Reference. Available from http://emedicine.medscape.com/article/335925.accessed 8 June 2011
8. Adams EM, Chow CK, Premkumar A, Plotz PH. The idiopathic inflammatory myopathies: Spectrum of MR imaging findings. Radiographics. 1995;15:563-574
9. Weber MA. Ultrasound in the inflammatory myopathies. Ann NY Acad Sci. 2009;1154:159-170
10. Jorizzo JL. Dermatomyositis: Practical aspects. Arch Dermatol. 2002; 138:114-116
11. Sibilia J, Chatelus E, Meyer A, Gottenberg JE, Sordet C, Goetz J. How can we diagnose and better understand inflammatory myopathies? The usefulness of auto-antibodies. Presse Med. 2010;39:1010-1025
12. Smith ES, Hallman JR, DeLuca AM, Goldenberg G, Jorizzo JL, Sangueza OP. Dermatomyositis: A clinicopathological study of 40 patients. Am J Dermatopathol. 2009;31:61-67
13. Elston DM, Ferringer T. Dermatopathology. Philadelphia: Elsevier Limited, 2009
14. Al-Mayouf S, Al-Mazyed A, Bahabri S. Efficacy of early treatment of severe juvenile dermatomyositis with intravenous methylprednisolone and methotrexate. Clin Rheumatol. 2000;19:138-141
15. Riley P, Maillard SM, Wedderburn LR, Woo P, Murray KJ, Pilkington CA. Intravenous cyclophosphamide pulse therapy in juvenile dermatomyositis. A review of efficacy and safety. Rheumatology Oxford. 2004;43:491-496
16. al-Janadi M, Smith CD, Karsh J. Cyclophosphamide treatment of interstitial pulmonary fibrosis in polymyositis/dermatomyositis. J Rheumatol. 1989;16:1592-1596
17. Gelber AC, Nousari HC, Wigley FM. Mycophenolate mofetil in the treatment of severe skin manifestations of dermatomyositis: A series of 4 cases. J Rheumatol. 2000;27:1542-1545
18. Majithia V, Harisdangkul V. Mycophenolate mofetil CellCept: An alternative therapy for autoimmune inflammatory myopathy. Rheumatology Oxford. 2005;44:386-389
19. Iorizzo LJ 3rd, Jorizzo JL. The treatment and prognosis of dermatomyositis: An updated review. J Am Acad Dermatol. 2008;59:99-112
20. Grossman JM, Gordon R, Ranganath VK, Deal C, Caplan L, Chen W, Curtis JR, Furst DE, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res Hoboken. 2010;62:1515-1526
21. de Salles Painelli V, Gualano B, Artioli GG, de Sá Pinto AL, Bonfá E, Lancha AH Jr, Lima FR. The possible role of physical exercise on the treatment of idiopathic inflammatory myopathies. Autoimmun Rev. 2009;8:355-359
22. Dalakas MC. Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis. Neurology. 1995;51(6 Suppl 5):S37-S45
23. Sinoway PA, Callen JP. Chlorambucil. An effective corticosteroidsparing agent for patients with recalcitrant dermatomyositis. Arthritis Rheum. 1993;36:319-324
24. Nawata Y, Kurasawa K, Takabayashi K, Miike S, Watanabe N, Hiraguri M, Kita Y, Kawai M, et al. Corticosteroid resistant interstitial pneumonitis in dermatomyositis/polymyositis: Prediction and treatment with cyclosporine. J Rheumatol. 1999;26:1527-1533
25. Kobayashi I, Yamada M, Takahashi Y, Kawamura N, Okano M, Sakiyama Y, Kobayashi K. Interstitial lung disease associated with juvenile dermatomyositis: Clinical features and efficacy of cyclosporin A. Rheumatology Oxford. 2003;42:371-374
26. Adams EM, Pucino F, Yarboro C, Hicks JE, Thornton B, McGarvey C, Sonies BC, Bartlett ML, et al. A pilot study: Use of fludarabine for refractory dermatomyositis and polymyositis, and examination of endpoint measures. J Rheumatol. 1998;26:352-360
27. Bunch TW. Prednisone and azathioprine for polymyositis: Long-term follow-up. Arthritis Rheum. 1981;24:45-48
28. Yamada A, Ohshima Y, Omata N, Yasutomi M, Mayumi M. Steroidsparing effect of tacrolimus in a patient with juvenile dermatomyositis presenting poor bioavailability of cyclosporine A. Eur J Pediatr. 2004; 163:561-562
29. Nadiminti U, Arbiser JL. Rapamycin sirolimus as a steroid-sparing agent in dermatomyositis. J Am Acad Dermatol. 2005;52(2 Suppl 1): 17-19
30. Hengstman GJ, van den Hoogen FH, Barrera P, Netea MG, Pieterse A, van de Putte LB, van Engelen BG. Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: Preliminary observations. Eur Neurol. 2003;50:10-15
31. Norman R, Greenberg RG, Jackson JM. Case reports of etanercept in inflammatory dermatoses. J Am Acad Dermatol. 2006;54:S139-S142
32. Levine TD. Rituximab in the treatment of dermatomyositis: An openlabel pilot study. Arthritis Rheum. 2005;52:601-607
33. Miller J, Walsh Y, Saminaden S, Lecky BRF, Winer JB. Randomised double blind trial of methotrexate and steroids compared with azathioprine and steroids in the treatment of idiopathic inflammatory myopathy. J Neurol Sci. 2002;199(Suppl 1):S53
34. Morganroth PA, Kreider ME, Werth VP. Mycophenolate mofetil for interstitial lung disease in dermatomyositis. Arthritis Care Res Hoboken. 2010;6210:1496-1501
35. Edge JC, Outland JD, Dempsey JR, Callen JP. Mycophenolate mofetil as an effective corticosteroid-sparing therapy for recalcitrant dermatomyositis. Arch Dermatol. 2006;142:65-69
36. Mok CC, To CH, Szeto ML. Successful treatment of dermatomyositisrelated rapidly progressive interstitial pneumonitis with sequential oral cyclophosphamide and azathioprine. Scand J Rheumatol. 2003; 32:181-183
37. Dalakas MC. Intravenous immunoglobulin in patients with anti-GAD antibody-associated neurological diseases and patients with inflammatory myopathies: Effects on clinicopathological features and immunoregulatory genes. Clin Rev Allergy Immunol. 2005;29:255-269
38. Levine TD. Rituximab in the treatment of dermatomyositis: An openlabel pilot study. Arthritis Rheum. 2005;52:601-607
39. Amato AA, Tawil R, Kissel J. A randomized, pilot trial of etanercept in dermatomyositis. Ann Neurol. 2011;70:427-436
40. Hollar CB, Jorizzo JL. Topical tacrolimus 0.1% ointment for refractory skin disease in dermatomyositis: A pilot study. J Dermatolog Treat. 2004;15:35-39
41. Ang GC, Werth VP. Combination antimalarials in the treatment of cutaneous dermatomyositis: A retrospective study. Arch Dermatol. 2005;141:855-859
42. Woo TY, Callen JP, Voorhees JJ, Bickers DR, Hanno R, Hawkins C. Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. J Am Acad Dermatol. 1984;10:592-600
43. Stirling DI. Thalidomide and its impact on dermatology. Semin Cutan Meg Surg. 1998;17:231-242
44. Dourmishev L, Meffert H, Piazena H. Dermatomyositis: Comparative studies of cutaneous photosensitivity in lupus erythematosus and normal subjects. Photodermatol Photoimmunol Photomed. 2004;20:230-234
45. Zahr ZA, Baer AN. Malignancy in myositis. Curr Rheumatol Rep. 2011;13:208-215
46. Andras C, Ponyi A, Constantin T. Dermatomyositis and polymyositis associated with malignancy: A 21-year retrospective study. J Rheumato. 2008;35:438-444
47. Chow WH, Gridley G, Mellemkjaer L, McLaughlin JK, Olsen JH, Fraumeni JF Jr. Cancer risk following polymyositis and dermatomyositis: A nationwide cohort study in Denmark. Cancer Causes Control. 1995;6:9-13
48. Hirakata M, Nagai S. Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheumatol. 2000;12:501-508